  -------------------------------------- -------------------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      ASUi005-A\
                                         ASUi006-A

  Alternative names of stem cell lines   ASU-161\
                                         ASU-487

  Institution                            Arizona State University; Tempe, AZ; USA

  Contact information of distributor     David Brafman, <David.Brafman@asu.edu>

  Type of cell lines                     iPSC

  Origin                                 Human

  Cell source                            Human peripheral blood mononuclear cells (PBMCs)

  Clonality                              Clonal

  Method of reprogramming                CytoTune^®^-iPS 2.0 Reprogramming System

  Multiline rationale                    Age-matched Alzheimer\'s disease and non-demented control hiPSC lines homozygous for the APOE 4 risk factor

  Gene modification                      No

  Type of modification                   N/A

  Associated disease                     Alzheimer\'s disease

  Gene/locus                             Apolipoprotein E (APOE)

  Method of modification                 N/A

  Name of transgene or resistance        N/A

  Inducible/constitutive system          N/A

  Date archived/stock date               March 2018

  Cell line repository/bank              Not applicable

  Ethical approval                       Mayo Clinic Institutional Review Board; IRB \# 15-008674
  -------------------------------------- -------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

Polymorphisms in the Apolipoprotein (APOE) gene have been identified as the most prevalent of the risk factors associated with sporadic Alzheimer\'s disease (AD). As such, hiPSCs with various APOE genotypes will provide a valuable resource to study the mechanisms by which this risk factor contributes to AD onset and progression.

Resource details {#S2}
================

Genome-wide association studies (GWAS) studies have identified several risk factors associated with increased probability of sporadic Alzheimer\'s disease (SAD) onset ([@R1]). Of these risk factors, polymorphism in the Apolipoprotein E (APOE) gene, a lipoprotein transporter involved in cholesterol metabolism, is the strongest and most prevalent ([@R3]). Compared to individuals with an APOE e3/3 genotype (referred to as the 'risk neutral' allele), heterozygosity for the e4 allele increases AD risk by 3 fold, and homozygosity for the e4 allele increases risk up to 12 fold ([@R5]). In this study, we report the generation of hiPSCs from two individuals from the Arizona APOE Cohort (for which recruitment and enrolment strategies have been described previously ([@R2])) that are homozygous for the APOE e4 allele--- a clinically diagnosed AD patient (ASUi005-A, Mini-Mental Status Exam \[MMSE\] score = Patient too advanced to collect data.) who fulfilled published diagnostic criteria ([@R4]) and an age-matched non-demented control patient (NDC; ASUi006-A, MMSE score = 29) ([Table 1](#T2){ref-type="table"}).

Peripheral blood mononuclear cells (PBMCs) were reprogrammed into hiPSCs using the non-integrating CytoTune^®^-iPS 2.0 Reprogramming System (Thermo Fisher Scientific). Several clones from each patient were isolated, expanded, and characterized by karyotyping and flow cytometry. One clone was expanded and fully characterized for each line ([Fig. 1](#F1){ref-type="fig"} and [Table 2](#T3){ref-type="table"}). The expanded hiPSC clones displayed a typical pluripotent stem cell morphology ([Fig. 1A](#F1){ref-type="fig"}). All expanded clones were confirmed to be negative for mycoplasma ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Sequencing analysis of the hiPSCs at the APOE gene in exon 4 confirm homozygosity at the e4 allele, identical to the parental PBMCs \[[Fig. 1B](#F1){ref-type="fig"}; Note: Human APOE has three major isoforms, ApoE2, ApoE3, and ApoE4, which differ by two amino acid substitutions at residues 112 and 158 in exon 4---ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), ApoE4 (Arg112, Arg158)\]. Expanded clones maintained a normal euploid karyotype ([Fig. 1C](#F1){ref-type="fig"}). Immunofluorescent staining ([Fig. 1D](#F1){ref-type="fig"}) and flow cytometry ([Fig. 1E](#F1){ref-type="fig"}) revealed that the hiPSCs expressed high levels of pluripotency-associated markers NANOG, OCT4, SOX2, and SSEA-4. Absence of viral transgenes in expanded clones was confirmed by RT-PCR ([Fig. 1F](#F1){ref-type="fig"}). Finally, to verify pluripotency, hiPSCs were spontaneously differentiated in vitro through embryoid body (EB) formation. Immunofluorescence ([Fig. 1G](#F1){ref-type="fig"}) and gene expression analysis ([Fig. 1H](#F1){ref-type="fig"}) of EBs revealed downregulation of pluripotency-associated markers (OCT4, NANOG, SOX2) and upregulation of genes associated with endoderm (AFP, SOX17), mesoderm (ACTC1, ISL1, SMA, TBX3), and ectoderm (B3T, MAP2, NCAM, PAX6).

Materials and methods {#S3}
=====================

Reprogramming of PBMCs {#S4}
----------------------

Peripheral blood samples were collected in BD Vacutainer cell preparation tubes and centrifuged for 30 min at 1800 RCF. Isolated PBMCs were cultured in expansion medium (EM; QBSF-60 \[Fisher Scientific\] supplemented with 100 μg/mL Primocin \[Fisher Scientific\], 1% penicillin/streptomycin \[Thermo Fisher\], 50 μg/mL ascorbic acid \[Sigma\], 50 ng/mL SCF \[R&D\], 10 ng/mL IL-3 \[R&D\], 2 U/mL EPO \[R& D\], 40 ng/mL IGF-1 \[R&D\], 1 μM Dexamethasone \[Sigma\]). After 9--12 days of expansion, 2.5 × 10^5^ PBMCs were resuspended in EM and transferred to a 12 well plate. Sendai viruses (SeV; CytoTune^®^-iPS 2.0 Reprogramming Kit \[Thermo Fisher\]) were added at a multiplicity of infection MOI of 10:10:6 for the hKOS:c-Myc:Klf4 Sendai viruses. Three days after transduction, cells were cultured on hESC-qualified Matrigel^®^ (Corning) in TeSR-E7 medium for 7 days, and then switched to TeSR-E8 (E8) medium (STEMCELL Technologies). After 21 days, individual hiPSC colonies were mechanically isolated and expanded in a 37 °C incubator with 5% CO~2~. After mechanically passaging for the first 3 passages, hiPSCs were non-enzymatically passaged using ReLeSR™ (STEMCELL Technologies) at a split ratio of 1:4--1:6 and cryopreserved. For routine passaging of these lines, Versene was used at a split ratio of 1:6 with 5 μM Rho kinase inhibitor (Y-27632; Biogems). Mycoplasma testing was performed with the MycoAlert PLUS kit (Lonza) and the Lucetta™ Luminometer (Lonza).

Quantitative RT-PCR (QPCR) {#S5}
--------------------------

RNA was isolated from cells (NucleoSpin RNA Kit, Clontech) and reverse transcription was performed (iScript RT Supermix, Bio-Rad). QPCR was carried out using SYBR green dye on a CFX384 Touch™ Real-Time PCR Detection System. QPCR experiments run with SYBR green dye were carried out using iTaq Universal SYBR Green Supermix (Bio-Rad). For qPCR experiments run with SYBR green dye, a 2 min gradient to 95 °C followed by 40 cycles at 95 °C for 5 s and 60 °C for 30 s was used. Primer sequences are provided in [Table 3](#T4){ref-type="table"}. Gene expression was normalized to 18S rRNA levels. Relative fold changes in gene expression were calculated using the 2 -- AACt method.

SeV detection {#S6}
-------------

After a minimum of 10 passages, RNA was isolated from cells (NucleoSpin RNA Kit, Clontech) and reverse transcription was performed (iScript RT Supermix, Bio-Rad). RT-PCR was run on a Bio-Rad CFX384 Real-Time System with the primers listed in [Table 3](#T4){ref-type="table"} and the following cycling parameters---a 2 min gradient to 95 °C followed by 20 cycles at 95 °C for 5 s and 60 °C for 30 s. The resulting products were then run on a 1% gel.

APOE genotyping {#S7}
---------------

For APOE genotyping via Sanger sequencing, genomic DNA was isolated from cells using the DNeasy kit (Qiagen). PCR was performed on a MultiGene OptiMax thermal cycler with the primers list in [Table 3](#T4){ref-type="table"} and the following cycling parameters---30 s at 98 °C followed by 35 cycles at 95 °C for 15 s, 62 °C for 30 s, and 72 °C for 30 s with a final extension of 10 min at 72 °C. The resulting PCR product was cleaned up using the PureLink™ PCR Purification Kit (ThermoFisher). Sanger sequencing was performed on PCR products (ASU CLAS Genomics Facility) uses Big Dye V3.1 chemistry with samples processed using an Applied Biosystems 3730XL Sequence Analysis Instrument.

Karyotyping and STR analysis {#S8}
----------------------------

Cytogenetic analysis was performed using standard protocols for G-banding (Baylor Miraca Genetics Laboratories). For ASUi005-A, cells were tested at passage 10, 20 metaphase cells were counted, and 4 cells were karyotyped. For ASUi006-A, cells were tested at passage 8, 20 metaphase cells were counted, and 3 cells were karyotyped. Short tandem repeat (STR) analysis was performed with Promega\'s PowerPlex^®^ 16 multiplex STR system (Cell Line Genetics). The following loci were tested: Amelogenin, CSF1PO, D13S317, D16S539, D18S51, D21S11, D3S1358, D5S818, D7S820, D8S1179, FGA, Penta D, Penta E, THO1, TPOX, vWA.

Flow cytometry {#S9}
--------------

Cells were dissociated with Accutase for 10 min at 37 °C, triturated, and passed through a 40 μm cell strainer. Cells were then washed twice with stain buffer (BD Biosciences) and resuspended at a maximum concentration of 5 × 10^6^ cells per 100 μL. Cells were fixed for 30 min at RT with BD Cytofix Fixation Buffer (BD Biosciences). The cells were then washed twice with stain buffer and permeabilized with BD Phosflow Perm Buffer III (BD Biosciences) for 30 min on ice. Cells were then washed twice with stain buffer. Antibodies were added at the dilution indicated in [Table 3](#T4){ref-type="table"} in 100 μL of cell suspension. Cells were stained with primary antibodies for 1 h on ice, washed, and resuspended in stain buffer. Cells were analyzed by an LSR II flow cytometer (BD Biosciences). Gates were determined using isotype only controls.

Immunofluorescence {#S10}
------------------

Cells were gently washed twice with PBS prior to fixation. Cells were then fixed for 20 min at room temperature (RT) with BD Cytofix Fixation Buffer (BD Biosciences). Cells were then washed twice with PBS and permeabilized with BD Phosflow Perm Buffer III (BD Biosciences) for 30 min at 4OC. Cells were then washed twice with PBS. Primary antibodies were incubated overnight at 4°C and then washed twice with PBS at RT. Secondary antibodies were incubated at RT for 1 h. Antibodies and the concentrations that were used are listed in [Table 3](#T4){ref-type="table"}. Nucleic acids were stained for DNA with Hoechst 33342 (2 μg/mL; ThermoFisher) for 10 min at RT and then washed twice with PBS. Imaging was performed using an EVOS FL Cell Imaging System (ThermoFisher).

In vitro embryoid body (EB) formation {#S11}
-------------------------------------

HiPSCs were harvested using ReLeSR™ (StemCell Technologies) and plated on low attachment plates in E8 medium. The following day, the media was changed to differentiation medium (DM; DMEM/F12, 20% FBS, 1% Pen/Strep). After 5 days, EBs were plated on Matrigel-coated plates and cultured with DM. After 14 days, cells were fixed, permeabilized, and stained for germ layer markers. In addition, cells were dissociated using Accutase, RNA was isolated (as described above for qPCR), and qPCR was performed (as described above for qPCR) to assess expression of pluripotency and germ layer markers.

Supplementary Material {#SM1}
======================
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Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2018.09.007>.

![(A) Phase contrast images of hiPSC lines. (B) Sanger sequencing showing maintenance of genotype at ApoE locus. (C) Karyotyping confirmed cells maintained a normal euploid karyotype. (D-E) Immunofluorescent and flow cytometry analysis of pluripotency markers (NANOG, OCT4, SOX2, SSEA4). (F) RT-PCR demonstrates absence of SeV vector. SeV infected fibroblasts were used as a positive control. (G) Immunofluorescent staining and (H) gene expression analysis of in vitro differentiated cells shows expression of markers associated with endoderm (AFP, SOX17), mesoderm (ACTC1, ISL1, SMA, TBX3), and ectoderm (B3T, MAP2, NCAM, PAX6).](nihms-1509780-f0001){#F1}

###### 

Summary of lines.

  iPSC line names   Abbreviation in figures   Gender   Age   Ethnicity   Genotype of locus   Disease
  ----------------- ------------------------- -------- ----- ----------- ------------------- ----------------------
  ASUi005-A         005                       M        87    N/A         APOE: 112R/158R     Alzheimer\'s disease
  ASUi006-A         006                       F        86    N/A         APOE: 112R/158R     Healthy/Non-Demented

###### 

Characterization and validation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification               Test                                        Result                                                                                                   Data
  ---------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                   Photography                                 Normal                                                                                                   [Fig. 1 A](#F1){ref-type="fig"}

  Phenotype                    Qualitative analysis: Immunocytochemistry   Positive staining for OCT4, NANOG, and SOX2                                                              [Fig. 1D](#F1){ref-type="fig"}

                               Quantitative analysis: Flow cytometry       OCT4/SSEA-4 Double Positive \> 95%                                                                       [Fig. 1E](#F1){ref-type="fig"}

  Genotype                     Karyotype (G-banding) and resolution        46XY (ASUi005-A)\                                                                                        [Fig. 1C](#F1){ref-type="fig"}
                                                                           46XX (ASUi006-A)\                                                                                        
                                                                           Resolution 450--550                                                                                      

  Identity                     Microsatellite PCR (mPCR)                   Not performed                                                                                            

                               STR analysis                                16 Loci All matched                                                                                      Available with the authors

  Mutation analysis            Sequencing\                                 Homozygous for Apolipoprotein e4 risk variant\                                                           [Fig. 1B](#F1){ref-type="fig"}
                               Southern Blot OR WGS                        Not performed                                                                                            

  Microbiology and virology    Mycoplasma                                  Mycoplasma testing by luminescence.\                                                                     [Supplementary Table 1](#SD1){ref-type="supplementary-material"}
                                                                           Negative                                                                                                 

  Differentiation potential    Embryoid body                               Endoderm (AFP, SOX17), mesoderm (ACTC1, ISL1, NKX2.5, TBX3, SMA), and ectoderm (B3T, NCAM, PAX6, MAP2)   [Fig. 1G and H](#F1){ref-type="fig"}

  Donor screening (OPTIONAL)   HIV 1+2 Hepatitis B, Hepatitis C            Not performed                                                                                            

  Genotype additional info     Blood group genotyping                      Not performed                                                                                            

   (OPTIONAL)                  HLA tissue typing                           Not performed                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagent details.

  Antibodies used for immunocytochemistry and flow cytometry                                              
  ------------------------------------------------------------ ---------------------------------- ------- --------------------------------------------
  Pluripotency markers                                         Mouse anti-OCT4                    1:50    Santa Cruz, Cat\# sc-5279 RRID: 628051
                                                               Mouse anti-NANOG                   1:50    Santa Cruz, Cat\# sc-293121 RRID: 10548762
                                                               Goat anti-SOX2                     1:50    Santa Cruz, Cat\# sc-17320 RRID: 2286684
                                                               Mouse IgG1 anti-OCT4-PE            1:10    BD Biosciences, Cat\# 560186 RRID: 1645331
                                                               Mouse IgG3 anti-SSEA4-APC          1:10    R&D Systems, Cat\# FAB1435A RRID: 494994
  Differentiation markers                                      Rabbit anti-AFP                    1:50    Santa Cruz, Cat\# sc-15375 RRID: 2223935
                                                               Mouse-anti SMA                     1:50    Santa Cruz, Cat\# sc-53015 RRID: 628683
                                                               Mouse anti-B3T                     1:100   Fitzgerald, Cat\# 10R-T136A RRID: 1289248
  Secondary antibodies                                         Alexa 488 Donkey anti-goat IgG     1:200   Thermo Fischer, Cat\# A11055 RRID: 2534102
                                                               Alexa 647 Donkey anti-mouse IgG    1:200   Thermo Fisher, Cat\# A31571 RRID: 162542
                                                               Alexa 488 Donkey anti-rabbit IgG   1:200   Thermo Fisher, Cat\# A21206 RRID: 141708
  Isotype control                                              Mouse IgG1-PE                      1:10    BD Biosciences, Cat\# 559320 RRID: 397218
                                                               Mouse IgG1-APC                     1:10    R&D Systems, Cat\# IC007A RRID: 952035

  Primers                                        
  ----------------------------- ---------- ----- ---------------------------------
  SeV Transgene (RT-PCR)        *SeV*      181   `GGATCACTAGGTGATATCGAGC`
                                                 `ACCAGACAAGAGTTTAAGAGATATGTATC`
  Pluripotency markers (qPCR)   *NANOG*    183   `CAATGGTGTGACGCAGGGAT`
                                                 `GGACTGTTCCAGGCCTGATT`
                                *OCT4*     164   `CAAAGCAGAAACCCTCGTGC`
                                                 `CTCGGACCACATCCTTCTCG`
                                *SOX2*     123   `GGATAAGTACACGCTGCCCG`
                                                 `ATGTGCGCGTAACTGTCCAT`
  Germ layer markers (qPCR)     *ACTC1*    179   `GTACCCTGGTATTGCTGATCG`
                                                 `CCTCATCGTACTCTTGCTTGCT`
                                *AFP*      301   `AGAGTTGCTAAAGGATACCAGGA`
                                                 `AGGCCAATAGTTTGTCCTCAC`
                                *ISL1*     135   `GGATTTGGAATGGCATGCGG`
                                                 `CATTTGATCCCGTACAACCTGA`
                                *MAP2*     111   `CCAGTTTCTGCGCCCAGATTT`
                                                 `AGCTCCCAATCAATGCTTCCT`
                                *NCAM*     77    `AGACCCCATTCCCTCCATCA`
                                                 `TGTGCCCATCCAGAGTCTTT`
                                *NKX2.5*   149   `GAGCCGAAAAGAAAGCCTGAA`
                                                 `CACCGACACGTCTCACTCAG`
                                *SOX17*    100   `GAATCCAGACCTGCACAACG`
                                                 `CTCTGCCTCCTCCACGAAG`
                                *TBX3*     212   `ATTTCACAATTCTCGGTGGA`
                                                 `TATAATTCCCCTGCCACGTA`
                                *PAX6*     100   `CTTCGCTAATGGGCCAGTGA`
                                                 `TCAGATTCCTATGCTGATTGGTGA`
  Housekeeping gene (qPCR)      *18s*      150   `GTAACCCGTTGAACCCCATT`
                                                 `CCATCCAATCGGTAGTAGCG`
  Genotyping (PCR)              *APOE*     244   `TAAGCTTGGCACGGCTGTCCAAGGA`
                                                 `ACAGAATTGGCCCCGGCCTGGTACAC`
